Search results
Results from the WOW.Com Content Network
Side effects can be severe and include infection, cardiac damage, hypertension, blurred vision, liver and kidney problems (tacrolimus nephrotoxicity), [26] hyperkalemia, hypomagnesemia, hyperglycemia, diabetes mellitus, itching, lung damage (sirolimus also causes lung damage), [27] and various neuropsychiatric problems such as loss of appetite ...
The mammalian target of rapamycin (mTOR), [5] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene. [6] [7] [8] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein ...
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
Side effects include irregular heartbeat, fatigue, high blood pressure, dry mouth, and eyes that are itchy, red, and/or swollen. Carbonic anhydrase inhibitors (Trusopt, Azopt): This is another ...
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's what a doctor wants you to know.
Ultimately, due to known side-effects of sirolimus, as well as inadequate evidence for optimal dosing, it was concluded in 2016 that more research was required before sirolimus could be widely prescribed for this purpose. [68] [73] Two human studies on the effects of sirolimus (rapamycin) on longevity did not show statistically significant ...
Sirolimus (rapamycin, trade name Rapamune) is a macrolide lactone, produced by the actinomycete bacterium Streptomyces hygroscopicus. It is used to prevent rejection reactions. Although it is a structural analogue of tacrolimus, it acts somewhat differently and has different side-effects.
Thus signaling upstream of mTORC1 still remains very active upon its inhibition via rapamycin and the rapalogs. Rapamycin and its analogues also have procoagulant side effects caused by off-target binding of the activated immunophilin FKBP12, which are not produced by structurally unrelated inhibitors of mTORC such as gedatolisib, WYE-687 and ...